{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T14:38:02Z","timestamp":1771511882894,"version":"3.50.1"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Shanghai Municipal Health Commission Clinical Research Youth Project","award":["20224Y0121"],"award-info":[{"award-number":["20224Y0121"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s00228-025-03944-1","type":"journal-article","created":{"date-parts":[[2026,1,3]],"date-time":"2026-01-03T07:47:27Z","timestamp":1767426447000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Cost-minimizing alternative dosage regimens of imipenem\/cilastatin\/relebactam for patients with renal impairment: a pharmacokinetic\/pharmacodynamic simulation study"],"prefix":"10.1007","volume":"82","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3272-5554","authenticated-orcid":false,"given":"Xiaoping","family":"Shi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Donghui","family":"Lao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qing","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoyu","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bijue","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qingfeng","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qianzhou","family":"Lv","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,2]]},"reference":[{"issue":"1","key":"3944_CR1","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s40265-017-0851-9","volume":"78","author":"GG Zhanel","year":"2018","unstructured":"Zhanel GG, Lawrence CK, Adam H et al (2018) Imipenem-relebactam and meropenem-vaborbactam: two novel carbapenem-\u03b2-lactamase inhibitor combinations. Drugs 78(1):65\u201398. https:\/\/doi.org\/10.1007\/s40265-017-0851-9","journal-title":"Drugs"},{"key":"3944_CR2","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00174-18","author":"KM Papp-Wallace","year":"2018","unstructured":"Papp-Wallace KM, Barnes MD, Alsop J et al (2018) Relebactam is a potent inhibitor of the KPC-2 \u03b2-lactamase and restores imipenem susceptibility in KPC-producing Enterobacteriaceae. Antimicrob Agents Chemother. https:\/\/doi.org\/10.1128\/aac.00174-18","journal-title":"Antimicrob Agents Chemother"},{"key":"3944_CR3","unstructured":"Merck S, Dohme Corp (2020) RECARBRIO\u2122 (imipenem\/cilastatin and relebactam) for injection, for intravenous use. Prescribing information"},{"key":"3944_CR4","unstructured":"Drugs.com Price of Drugs Information from Drugs.com. https:\/\/www.drugs.com\/. Accessed 15 March 2024"},{"key":"3944_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.iccn.2023.103403","volume":"77","author":"P Jarrett","year":"2023","unstructured":"Jarrett P, Keogh S, Roberts JA, Wallis SC, Coyer FM (2023) Antimicrobial residual drug error in the intensive care unit; a single blinded prospective observational study. Intensive Crit Care Nurs 77:103403. https:\/\/doi.org\/10.1016\/j.iccn.2023.103403","journal-title":"Intensive Crit Care Nurs"},{"key":"3944_CR6","unstructured":"Centers for Disease Control and Prevention, National Center for Emerging and Zoonotic Infectious Diseases (NCEZID), & Division of Healthcare Quality Promotion (DHQP) (2023) Protect Patients Against Preventable Harm from Improper Use of Single\u2013Dose\/Single\u2013Use Vials. https:\/\/www.cdc.gov\/injection-safety\/hcp\/clinical-safety\/?CDC_AAref_Val=https:\/\/www.cdc.gov\/injectionsafety\/CDCposition-SingleUseVial.html. Accessed 22 December 2023"},{"issue":"1","key":"3944_CR7","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.bjid.2012.09.005","volume":"17","author":"S Baniasadi","year":"2013","unstructured":"Baniasadi S, Dorudinia A, Mobarhan M, Karimi Gamishan M, Fahimi F (2013) Microbial contamination of single- and multiple-dose vials after opening in a pulmonary teaching hospital. Braz J Infect Dis 17(1):69\u201373. https:\/\/doi.org\/10.1016\/j.bjid.2012.09.005","journal-title":"Braz J Infect Dis"},{"issue":"3","key":"3944_CR8","doi-asserted-by":"publisher","first-page":"e0210421","DOI":"10.1128\/aac.02104-21","volume":"66","author":"L Dheyriat","year":"2022","unstructured":"Dheyriat L, Bourguignon L, Perpoint T, Ferry T, Goutelle S (2022) Pharmacokinetic\/pharmacodynamic simulations of cost-effective dosage regimens of Ceftolozane-Tazobactam and Ceftazidime-Avibactam in patients with renal impairment. Antimicrob Agents Chemother 66(3):e0210421. https:\/\/doi.org\/10.1128\/aac.02104-21","journal-title":"Antimicrob Agents Chemother"},{"issue":"10","key":"3944_CR9","doi-asserted-by":"publisher","first-page":"748","DOI":"10.1002\/psp4.12462","volume":"8","author":"P Bhagunde","year":"2019","unstructured":"Bhagunde P, Patel P, Lala M et al (2019) Population pharmacokinetic analysis for Imipenem-Relebactam in healthy volunteers and patients with bacterial infections. CPT: pharmacometrics & systems pharmacology 8(10):748\u2013758. https:\/\/doi.org\/10.1002\/psp4.12462","journal-title":"CPT: pharmacometrics & systems pharmacology"},{"issue":"2","key":"3944_CR10","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1111\/cts.13158","volume":"15","author":"M Patel","year":"2022","unstructured":"Patel M, Bellanti F, Daryani NM et al (2022) Population pharmacokinetic\/pharmacodynamic assessment of imipenem\/cilastatin\/relebactam in patients with hospital-acquired\/ventilator-associated bacterial pneumonia. Clin Transl Sci 15(2):396\u2013408. https:\/\/doi.org\/10.1111\/cts.13158","journal-title":"Clin Transl Sci"},{"key":"3944_CR11","volume-title":"Performance Standards for Antimicrobial Susceptibility Testing","author":"Clinical and Laboratory Standards Institute (CLSI)","year":"2023","unstructured":"Clinical and Laboratory Standards Institute (CLSI) (2023) Performance Standards for Antimicrobial Susceptibility Testing, 33th ed. Clinical and Laboratory Standards Institute, Wayne, PA","edition":"33th ed"},{"key":"3944_CR12","doi-asserted-by":"publisher","DOI":"10.1128\/aac.02323-17","author":"J Wu","year":"2018","unstructured":"Wu J, Racine F, Wismer MK et al (2018) Exploring the pharmacokinetic\/pharmacodynamic relationship of relebactam (MK-7655) in combination with imipenem in a hollow-fiber infection model. Antimicrob Agents Chemother. https:\/\/doi.org\/10.1128\/aac.02323-17","journal-title":"Antimicrob Agents Chemother"},{"key":"3944_CR13","unstructured":"Food and Drug Administration (2019) FDA NDA 212819. Food and Drug Administration Multi-Discipline Review for RECARBRIO\u2122 (Imipenem, cilastatin and relebactam). https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2019\/212819Orig1s000MultidisciplineR.pdf. Accessed June 2025"},{"key":"3944_CR14","volume-title":"PRIMAXIN\u2122 (imipenem and cilastatin) for Injection, for intravenous use","author":"Merck Sharp & Dohme Corp","year":"2022","unstructured":"Merck Sharp & Dohme Corp (2022) PRIMAXIN\u2122 (imipenem and cilastatin) for Injection, for intravenous use. Prescribing information"},{"key":"3944_CR15","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00280-18","author":"EG Rhee","year":"2018","unstructured":"Rhee EG, Rizk ML, Calder N et al (2018) Pharmacokinetics, safety, and tolerability of single and multiple doses of relebactam, a \u03b2-lactamase inhibitor, in combination with imipenem and cilastatin in healthy participants. Antimicrob Agents Chemother. https:\/\/doi.org\/10.1128\/aac.00280-18","journal-title":"Antimicrob Agents Chemother"},{"issue":"6","key":"3944_CR16","doi-asserted-by":"publisher","first-page":"R184","DOI":"10.1186\/cc2388","volume":"7","author":"AR van Zanten","year":"2003","unstructured":"van Zanten AR, Engelfriet PM, van Dillen K et al (2003) Importance of nondrug costs of intravenous antibiotic therapy. Crit Care 7(6):R184\u2013190. https:\/\/doi.org\/10.1186\/cc2388","journal-title":"Crit Care"},{"issue":"2","key":"3944_CR17","doi-asserted-by":"publisher","DOI":"10.1093\/jacamr\/dlad011","volume":"5","author":"JA Roberts","year":"2023","unstructured":"Roberts JA, Nicolau DP, Martin-Loeches I et al (2023) Imipenem\/cilastatin\/relebactam efficacy, safety and probability of target attainment in adults with hospital-acquired or ventilator-associated bacterial pneumonia among patients with baseline renal impairment, normal renal function, and augmented renal clearance. JAC-antimicrobial resistance 5(2):dlad011. https:\/\/doi.org\/10.1093\/jacamr\/dlad011","journal-title":"JAC-antimicrobial resistance"},{"issue":"11","key":"3944_CR18","doi-asserted-by":"publisher","first-page":"e4539","DOI":"10.1093\/cid\/ciaa803","volume":"73","author":"I Titov","year":"2021","unstructured":"Titov I, Wunderink RG, Roquilly A et al (2021) A randomized, double-blind, multicenter trial comparing efficacy and safety of Imipenem\/Cilastatin\/Relebactam versus Piperacillin\/Tazobactam in adults with hospital-acquired or ventilator-associated bacterial pneumonia (RESTORE-IMI 2 Study). Clin Infect Dis 73(11):e4539\u2013e4548. https:\/\/doi.org\/10.1093\/cid\/ciaa803","journal-title":"Clin Infect Dis"},{"key":"3944_CR19","doi-asserted-by":"publisher","DOI":"10.1128\/aac.02203-19","author":"KS Kaye","year":"2020","unstructured":"Kaye KS, Boucher HW, Brown ML et al (2020) Comparison of treatment outcomes between analysis populations in the RESTORE-IMI 1 phase 3 trial of Imipenem-Cilastatin-Relebactam versus Colistin plus Imipenem-Cilastatin in patients with Imipenem-Nonsusceptible bacterial infections. Antimicrob Agents Chemother. https:\/\/doi.org\/10.1128\/aac.02203-19","journal-title":"Antimicrob Agents Chemother"},{"issue":"5","key":"3944_CR20","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.ijantimicag.2014.01.027","volume":"43","author":"J Teo","year":"2014","unstructured":"Teo J, Liew Y, Lee W, Kwa AL (2014) Prolonged infusion versus intermittent boluses of \u03b2-lactam antibiotics for treatment of acute infections: a meta-analysis. Int J Antimicrob Agents 43(5):403\u2013411. https:\/\/doi.org\/10.1016\/j.ijantimicag.2014.01.027","journal-title":"Int J Antimicrob Agents"},{"issue":"11","key":"3944_CR21","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1345\/aph.1M304","volume":"43","author":"KM Shea","year":"2009","unstructured":"Shea KM, Cheatham SC, Smith DW et al (2009) Comparative pharmacodynamics of intermittent and prolonged infusions of piperacillin\/tazobactam using Monte Carlo simulations and steady-state pharmacokinetic data from hospitalized patients. Ann Pharmacother 43(11):1747\u20131754. https:\/\/doi.org\/10.1345\/aph.1M304","journal-title":"Ann Pharmacother"},{"issue":"3","key":"3944_CR22","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1093\/jac\/dkn543","volume":"63","author":"S Jaruratanasirikul","year":"2009","unstructured":"Jaruratanasirikul S, Sudsai T (2009) Comparison of the pharmacodynamics of Imipenem in patients with ventilator-associated pneumonia following administration by 2 or 0.5\u00a0h infusion. J Antimicrob Chemother 63(3):560\u2013563. https:\/\/doi.org\/10.1093\/jac\/dkn543","journal-title":"J Antimicrob Chemother"},{"issue":"3","key":"3944_CR23","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/j.diagmicrobio.2010.06.012","volume":"68","author":"LS Lee","year":"2010","unstructured":"Lee LS, Kinzig-Schippers M, Nafziger AN et al (2010) Comparison of 30-min and 3-h infusion regimens for imipenem\/cilastatin and for meropenem evaluated by Monte Carlo simulation. Diagn Microbiol Infect Dis 68(3):251\u2013258. https:\/\/doi.org\/10.1016\/j.diagmicrobio.2010.06.012","journal-title":"Diagn Microbiol Infect Dis"},{"key":"3944_CR24","doi-asserted-by":"publisher","first-page":"2677","DOI":"10.2147\/dddt.S143021","volume":"11","author":"MM Ibrahim","year":"2017","unstructured":"Ibrahim MM, Tammam TF, Ebaed MED et al (2017) Extended infusion versus intermittent infusion of Imipenem in the treatment of ventilator-associated pneumonia. Drug Des Devel Ther 11:2677\u20132682. https:\/\/doi.org\/10.2147\/dddt.S143021","journal-title":"Drug Des Devel Ther"},{"issue":"Suppl 1","key":"3944_CR25","doi-asserted-by":"publisher","first-page":"S16","DOI":"10.1002\/jhm.869","volume":"6","author":"TP Lodise","year":"2011","unstructured":"Lodise TP, Butterfield J (2011) Use of pharmacodynamic principles to inform \u03b2-lactam dosing: S does not always mean success. J Hosp Med 6(Suppl 1):S16\u201323. https:\/\/doi.org\/10.1002\/jhm.869","journal-title":"J Hosp Med"},{"issue":"8","key":"3944_CR26","doi-asserted-by":"publisher","first-page":"2327","DOI":"10.1128\/aac.46.8.2327-2332.2002","volume":"46","author":"E Viaene","year":"2002","unstructured":"Viaene E, Chanteux H, Servais H, Mingeot-Leclercq MP, Tulkens PM (2002) Comparative stability studies of antipseudomonal beta-lactams for potential administration through portable elastomeric pumps (home therapy for cystic fibrosis patients) and motor-operated syringes (intensive care units). Antimicrob Agents Chemother 46(8):2327\u20132332. https:\/\/doi.org\/10.1128\/aac.46.8.2327-2332.2002","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"3944_CR27","doi-asserted-by":"publisher","DOI":"10.1177\/15593258211059325","volume":"19","author":"C Sornsuvit","year":"2021","unstructured":"Sornsuvit C, Wientong P, Uitrakul S, Okonogi S, Katip W (2021) Influence of concentration and temperature on stability of Imipenem focused on solutions for extended infusion. Dose Response 19(4):15593258211059325. https:\/\/doi.org\/10.1177\/15593258211059325","journal-title":"Dose Response"},{"issue":"18","key":"3944_CR28","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1093\/ajhp\/zxaa199","volume":"77","author":"CM Forshay","year":"2020","unstructured":"Forshay CM, Hansen KN, Eckel SF (2020) Using intravenous pump infusion data to optimize continuous infusion concentrations and reduce drug and fluid waste. Am J Health-Syst Pharm 77(18):1497\u20131503. https:\/\/doi.org\/10.1093\/ajhp\/zxaa199","journal-title":"Am J Health-Syst Pharm"},{"issue":"3","key":"3944_CR29","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1177\/0018578718786943","volume":"54","author":"E Palacios Rosas","year":"2019","unstructured":"Palacios Rosas E, Soria-Cedillo IF, Puertolas-Balint F et al (2019) Impact of implementing smart infusion pumps in an intensive care unit in Mexico: a pre-post cost analysis based on intravenous solutions consumption. Hosp Pharm 54(3):203\u2013208. https:\/\/doi.org\/10.1177\/0018578718786943","journal-title":"Hosp Pharm"},{"issue":"10","key":"3944_CR30","doi-asserted-by":"publisher","first-page":"6234","DOI":"10.1128\/aac.00633-16","volume":"60","author":"C Lucasti","year":"2016","unstructured":"Lucasti C, Vasile L, Sandesc D et al (2016) Phase 2, dose-ranging study of relebactam with Imipenem-Cilastatin in subjects with complicated intra-abdominal infection. Antimicrob Agents Chemother 60(10):6234\u20136243. https:\/\/doi.org\/10.1128\/aac.00633-16","journal-title":"Antimicrob Agents Chemother"},{"issue":"9","key":"3944_CR31","doi-asserted-by":"publisher","first-page":"2616","DOI":"10.1093\/jac\/dkx139","volume":"72","author":"M Sims","year":"2017","unstructured":"Sims M, Mariyanovski V, McLeroth P et al (2017) Prospective, randomized, double-blind, phase 2 dose-ranging study comparing efficacy and safety of imipenem\/cilastatin plus relebactam with imipenem\/cilastatin alone in patients with complicated urinary tract infections. J Antimicrob Chemother 72(9):2616\u20132626. https:\/\/doi.org\/10.1093\/jac\/dkx139","journal-title":"J Antimicrob Chemother"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-025-03944-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-025-03944-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-025-03944-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T13:39:18Z","timestamp":1771508358000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00228-025-03944-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["3944"],"URL":"https:\/\/doi.org\/10.1007\/s00228-025-03944-1","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"18 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"21"}}